Zacks Small Cap Has Negative Outlook of BCLI FY2024 Earnings

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) – Research analysts at Zacks Small Cap reduced their FY2024 earnings per share (EPS) estimates for Brainstorm Cell Therapeutics in a report issued on Monday, January 6th. Zacks Small Cap analyst D. Bautz now anticipates that the biotechnology company will post earnings of ($3.01) per share for the year, down from their prior forecast of ($2.85). The consensus estimate for Brainstorm Cell Therapeutics’ current full-year earnings is ($2.85) per share. Zacks Small Cap also issued estimates for Brainstorm Cell Therapeutics’ Q4 2024 earnings at ($0.49) EPS, FY2025 earnings at ($1.60) EPS and FY2026 earnings at ($1.33) EPS.

Separately, StockNews.com raised Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th.

Brainstorm Cell Therapeutics Trading Down 2.6 %

Shares of NASDAQ:BCLI opened at $2.23 on Wednesday. The stock has a market capitalization of $12.72 million, a PE ratio of -0.46 and a beta of 0.29. Brainstorm Cell Therapeutics has a 1 year low of $1.05 and a 1 year high of $11.89. The firm has a fifty day moving average price of $1.74 and a 200 day moving average price of $3.33.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC bought a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the second quarter, according to its most recent filing with the SEC. The firm bought 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned about 11.30% of Brainstorm Cell Therapeutics at the end of the most recent quarter. 14.33% of the stock is currently owned by hedge funds and other institutional investors.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.